论文部分内容阅读
目的:评价乌司他丁与生长抑素联用治疗AP患者的临床价值。方法:选取2013年8月—2014年10月间诊治的AP患者104例,将其分为对照组和观察组(每组52例),两组患者均予常规治疗;对照组患者在常规治疗的基础上予生长抑素治疗,观察组患者在对照组的基础上加用乌司他丁治疗,评价两组患者的临床疗效。结果:观察组患者临床治疗的总有效率为94.23%优于对照组为80.77%(P<0.05);观察组患者临床症状的改善时间、住院时间短于对照组(P<0.05);两组患者并发症(假性胰腺脓肿)的发生率经比较其差异无统计学意义(P>0.05)。结论:乌司他丁与生长抑素联用治疗AP患者临床疗效确切,促进了患者的康复,有效缩短了其住院时间,减轻患者经济负担。
Objective: To evaluate the clinical value of ulinastatin combined with somatostatin in the treatment of AP. Methods: A total of 104 AP patients diagnosed and treated between August 2013 and October 2014 were selected and divided into control group and observation group (52 cases in each group). Both groups were treated routinely. In the control group, Based on the somatostatin treatment, the observation group patients in the control group based on the use of ulinastatin treatment, evaluation of two groups of patients with clinical efficacy. Results: The total effective rate of clinical observation in the observation group was 94.23%, which was significantly higher than that in the control group (80.77%, P <0.05). The clinical symptoms in the observation group were shorter than those in the control group (P <0.05) The incidence of patients with complications (pseudo-pancreatic abscess) compared with no significant difference (P> 0.05). Conclusion: The clinical efficacy of ulinastatin combined with somatostatin in the treatment of AP patients is exact, which has promoted the rehabilitation of patients and effectively shortened the length of hospital stay and the economic burden of patients.